Which has higher earnings and valuation, STOK or ALKS?

Alkermes has higher revenue and earnings than Stoke Therapeutics. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Stoke Therapeutics $184.42M 10.16 -$6.89M -$3.34 N/A Alkermes $1.67B 4.62 $241.66M $0.38 120.97

Does the media prefer STOK or ALKS?

In the previous week, Alkermes had 3 more articles in the media than Stoke Therapeutics. MarketBeat recorded 6 mentions for Alkermes and 3 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 1.77 beat Alkermes' score of 0.99 indicating that Stoke Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Alkermes 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SYRE or STOK?

In the previous week, Spyre Therapeutics had 14 more articles in the media than Stoke Therapeutics. MarketBeat recorded 17 mentions for Spyre Therapeutics and 3 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 1.77 beat Spyre Therapeutics' score of 0.70 indicating that Stoke Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stoke Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor RYTM or STOK?

In the previous week, Rhythm Pharmaceuticals had 3 more articles in the media than Stoke Therapeutics. MarketBeat recorded 6 mentions for Rhythm Pharmaceuticals and 3 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 1.77 beat Rhythm Pharmaceuticals' score of 1.16 indicating that Stoke Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stoke Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to SRRK or STOK?

In the previous week, Scholar Rock had 8 more articles in the media than Stoke Therapeutics. MarketBeat recorded 11 mentions for Scholar Rock and 3 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 1.77 beat Scholar Rock's score of 0.61 indicating that Stoke Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stoke Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor STOK or CGON?

In the previous week, CG Oncology had 3 more articles in the media than Stoke Therapeutics. MarketBeat recorded 6 mentions for CG Oncology and 3 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 1.77 beat CG Oncology's score of 1.35 indicating that Stoke Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive CG Oncology 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Stoke Therapeutics (STOK) Competitors

$29.03 -0.31 (-1.06%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$29.00 -0.04 (-0.12%)

As of 09/11/2026 07:59 PM Eastern

Compare

STOK vs. ALKS, SYRE, RYTM, SRRK, and CGON

Should you buy Stoke Therapeutics stock or one of its competitors? Stoke Therapeutics's main competitors and comparable companies include Alkermes (ALKS), Spyre Therapeutics (SYRE), Rhythm Pharmaceuticals (RYTM), Scholar Rock (SRRK), and CG Oncology (CGON). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Stoke Therapeutics compare to Alkermes?

Stoke Therapeutics (NASDAQ:STOK) and Alkermes (NASDAQ:ALKS) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

95.2% of Alkermes shares are owned by institutional investors. 9.6% of Stoke Therapeutics shares are owned by insiders. Comparatively, 4.6% of Alkermes shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Stoke Therapeutics currently has a consensus target price of $44.25, suggesting a potential upside of 52.43%. Alkermes has a consensus target price of $54.56, suggesting a potential upside of 18.69%. Given Stoke Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Stoke Therapeutics is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Alkermes	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72

Alkermes has a net margin of 3.96% compared to Stoke Therapeutics' net margin of -753.60%. Alkermes' return on equity of 4.15% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-753.60%	-59.36%	-51.46%
Alkermes	3.96%	4.15%	2.19%

Alkermes has higher revenue and earnings than Stoke Therapeutics. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$184.42M	10.16	-$6.89M	-$3.34	N/A
Alkermes	$1.67B	4.62	$241.66M	$0.38	120.97

In the previous week, Alkermes had 3 more articles in the media than Stoke Therapeutics. MarketBeat recorded 6 mentions for Alkermes and 3 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 1.77 beat Alkermes' score of 0.99 indicating that Stoke Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stoke Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Alkermes	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Stoke Therapeutics has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market. Comparatively, Alkermes has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

Summary

Alkermes beats Stoke Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Stoke Therapeutics compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Stoke Therapeutics (NASDAQ:STOK) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

In the previous week, Spyre Therapeutics had 14 more articles in the media than Stoke Therapeutics. MarketBeat recorded 17 mentions for Spyre Therapeutics and 3 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 1.77 beat Spyre Therapeutics' score of 0.70 indicating that Stoke Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stoke Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Spyre Therapeutics has a beta of 2.99, indicating that its share price is 199% more volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market.

80.4% of Spyre Therapeutics shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by company insiders. Comparatively, 9.6% of Stoke Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Stoke Therapeutics has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	N/A	N/A	-$155.20M	-$1.95	N/A
Stoke Therapeutics	$184.42M	10.16	-$6.89M	-$3.34	N/A

Spyre Therapeutics presently has a consensus price target of $109.69, suggesting a potential upside of 21.07%. Stoke Therapeutics has a consensus price target of $44.25, suggesting a potential upside of 52.43%. Given Stoke Therapeutics' higher possible upside, analysts plainly believe Stoke Therapeutics is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Stoke Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Spyre Therapeutics has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -753.60%. Spyre Therapeutics' return on equity of -30.74% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-30.74%	-22.23%
Stoke Therapeutics	-753.60%	-59.36%	-51.46%

Summary

Spyre Therapeutics beats Stoke Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Stoke Therapeutics compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Stoke Therapeutics (NASDAQ:STOK) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

In the previous week, Rhythm Pharmaceuticals had 3 more articles in the media than Stoke Therapeutics. MarketBeat recorded 6 mentions for Rhythm Pharmaceuticals and 3 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 1.77 beat Rhythm Pharmaceuticals' score of 1.16 indicating that Stoke Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stoke Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Rhythm Pharmaceuticals presently has a consensus price target of $141.12, indicating a potential upside of 34.77%. Stoke Therapeutics has a consensus price target of $44.25, indicating a potential upside of 52.43%. Given Stoke Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Stoke Therapeutics is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.74
Stoke Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Stoke Therapeutics has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	37.82	-$196.54M	-$3.11	N/A
Stoke Therapeutics	$184.42M	10.16	-$6.89M	-$3.34	N/A

Rhythm Pharmaceuticals has a beta of 1.97, meaning that its share price is 97% more volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market.

Rhythm Pharmaceuticals has a net margin of -85.59% compared to Stoke Therapeutics' net margin of -753.60%. Stoke Therapeutics' return on equity of -59.36% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%
Stoke Therapeutics	-753.60%	-59.36%	-51.46%

Summary

Rhythm Pharmaceuticals beats Stoke Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Stoke Therapeutics compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Stoke Therapeutics (NASDAQ:STOK) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

Stoke Therapeutics has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A
Stoke Therapeutics	$184.42M	10.16	-$6.89M	-$3.34	N/A

Scholar Rock has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market.

In the previous week, Scholar Rock had 8 more articles in the media than Stoke Therapeutics. MarketBeat recorded 11 mentions for Scholar Rock and 3 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 1.77 beat Scholar Rock's score of 0.61 indicating that Stoke Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stoke Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

91.1% of Scholar Rock shares are held by institutional investors. 10.3% of Scholar Rock shares are held by insiders. Comparatively, 9.6% of Stoke Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Scholar Rock presently has a consensus target price of $58.77, suggesting a potential upside of 6.06%. Stoke Therapeutics has a consensus target price of $44.25, suggesting a potential upside of 52.43%. Given Stoke Therapeutics' higher probable upside, analysts clearly believe Stoke Therapeutics is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	4 Strong Buy rating(s)	3.06
Stoke Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Scholar Rock has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -753.60%. Stoke Therapeutics' return on equity of -59.36% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-160.19%	-87.18%
Stoke Therapeutics	-753.60%	-59.36%	-51.46%

Summary

Stoke Therapeutics beats Scholar Rock on 9 of the 15 factors compared between the two stocks.

How does Stoke Therapeutics compare to CG Oncology?

Stoke Therapeutics (NASDAQ:STOK) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

26.6% of CG Oncology shares are owned by institutional investors. 9.6% of Stoke Therapeutics shares are owned by company insiders. Comparatively, 4.8% of CG Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Stoke Therapeutics has a net margin of -753.60% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -25.20% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-753.60%	-59.36%	-51.46%
CG Oncology	-3,602.68%	-25.20%	-23.98%

Stoke Therapeutics has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$184.42M	10.16	-$6.89M	-$3.34	N/A
CG Oncology	$6.23M	1,029.72	-$160.99M	-$2.69	N/A

Stoke Therapeutics has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market. Comparatively, CG Oncology has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

In the previous week, CG Oncology had 3 more articles in the media than Stoke Therapeutics. MarketBeat recorded 6 mentions for CG Oncology and 3 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 1.77 beat CG Oncology's score of 1.35 indicating that Stoke Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stoke Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
CG Oncology	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Stoke Therapeutics currently has a consensus target price of $44.25, suggesting a potential upside of 52.43%. CG Oncology has a consensus target price of $87.78, suggesting a potential upside of 21.32%. Given Stoke Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Stoke Therapeutics is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Stoke Therapeutics beats CG Oncology on 10 of the 16 factors compared between the two stocks.

Get Stoke Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STOK vs. The Competition

Export

Metric	Stoke Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.89B	$3.84B	$7.13B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-8.69	14.25	275.24	25.29
Price / Sales	10.16	1,473.16	656.02	98.94
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	4.71	15.12	10.33	6.20
Net Income	-$6.89M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-2.62%	-4.34%	-3.32%	-2.35%
1 Month Performance	-11.95%	-0.02%	-0.41%	-2.77%
1 Year Performance	23.74%	40.64%	19.21%	7.63%

Stoke Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STOK Stoke Therapeutics	3.4499 of 5 stars	$29.03 -1.1%	$44.25 +52.4%	+21.6%	$1.89B	$184.42M	N/A	170	Positive News Analyst Forecast
ALKS Alkermes	2.8632 of 5 stars	$46.99 -0.9%	$54.56 +16.1%	+65.9%	$7.95B	$1.48B	123.66	2,050	News Coverage
SYRE Spyre Therapeutics	2.4172 of 5 stars	$89.33 -1.1%	$109.69 +22.8%	+459.3%	$7.95B	$890K	N/A	73	Analyst Forecast
RYTM Rhythm Pharmaceuticals	2.855 of 5 stars	$106.13 -1.0%	$141.12 +33.0%	+6.9%	$7.34B	$189.76M	N/A	140	Positive News
SRRK Scholar Rock	1.801 of 5 stars	$56.80 -1.7%	$58.77 +3.5%	+74.0%	$7.04B	N/A	N/A	140	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STOK) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Stoke Therapeutics (STOK) Competitors

STOK vs. ALKS, SYRE, RYTM, SRRK, and CGON

How does Stoke Therapeutics compare to Alkermes?

Summary

How does Stoke Therapeutics compare to Spyre Therapeutics?

Summary

How does Stoke Therapeutics compare to Rhythm Pharmaceuticals?

Summary

How does Stoke Therapeutics compare to Scholar Rock?

Summary

How does Stoke Therapeutics compare to CG Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STOK vs. The Competition

Stoke Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Stoke Therapeutics (STOK) Competitors

STOK vs. ALKS, SYRE, RYTM, SRRK, and CGON

How does Stoke Therapeutics compare to Alkermes?

Do insiders and institutionals have more ownership in STOK or ALKS?

Do analysts recommend STOK or ALKS?

Is STOK or ALKS more profitable?

Which has higher earnings and valuation, STOK or ALKS?

Does the media prefer STOK or ALKS?

Which has more risk and volatility, STOK or ALKS?

Summary

How does Stoke Therapeutics compare to Spyre Therapeutics?

Does the media refer more to SYRE or STOK?

Which has more risk & volatility, SYRE or STOK?

Do institutionals and insiders have more ownership in SYRE or STOK?

Which has higher valuation & earnings, SYRE or STOK?

Do analysts prefer SYRE or STOK?

Is SYRE or STOK more profitable?

Summary

How does Stoke Therapeutics compare to Rhythm Pharmaceuticals?

Does the media favor RYTM or STOK?

Do analysts rate RYTM or STOK?

Which has preferable valuation and earnings, RYTM or STOK?

Which has more volatility & risk, RYTM or STOK?

Is RYTM or STOK more profitable?

Summary

How does Stoke Therapeutics compare to Scholar Rock?

Which has higher valuation and earnings, SRRK or STOK?

Which has more volatility & risk, SRRK or STOK?

Does the media refer more to SRRK or STOK?

Do institutionals and insiders believe in SRRK or STOK?

Do analysts prefer SRRK or STOK?

Is SRRK or STOK more profitable?

Summary

How does Stoke Therapeutics compare to CG Oncology?

Do institutionals and insiders hold more shares of STOK or CGON?

Is STOK or CGON more profitable?

Which has higher earnings & valuation, STOK or CGON?

Which has more risk & volatility, STOK or CGON?

Does the media favor STOK or CGON?

Do analysts prefer STOK or CGON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STOK vs. The Competition

Stoke Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools